Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.
Sheng-Ru Shiou, Pran K Datta, Punita Dhawan, Brian K Law, Jonathan M Yingling, Dan A Dixon, R Daniel Beauchamp
Index: J. Biol. Chem. 281 , 33971-33981, (2006)
Full Text: HTML
Abstract
Metastasis is a primary cause of mortality due to cancer. Early metastatic growth involves both a remodeling of the extracellular matrix surrounding tumors and invasion of tumors across the basement membrane. Up-regulation of extracellular matrix degrading proteases such as urokinase plasminogen activator (uPA) and matrix metalloproteinases has been reported to facilitate tumor cell invasion. Autocrine transforming growth factor-beta (TGF-beta) signaling may play an important role in cancer cell invasion and metastasis; however, the underlying mechanisms remain unclear. In the present study, we report that autocrine TGF-beta supports cancer cell invasion by maintaining uPA levels through protein secretion. Interestingly, treatment of paracrine/exogenous TGF-beta at higher concentrations than autocrine TGF-beta further enhanced uPA expression and cell invasion. The enhanced uPA expression by exogenous TGF-beta is a result of increased uPA mRNA expression due to RNA stabilization. We observed that both autocrine and paracrine TGF-beta-mediated regulation of uPA levels was lost upon depletion of Smad4 protein by RNA interference. Thus, through the Smad pathway, autocrine TGF-beta maintains uPA expression through facilitated protein secretion, thereby supporting tumor cell invasiveness, whereas exogenous TGF-beta further enhances uPA expression through mRNA stabilization leading to even greater invasiveness of the cancer cells.
Related Compounds
Related Articles:
2003-09-11
[J. Med. Chem. 46 , 3953-3956, (2003)]
2006-03-23
[J. Med. Chem. 49 , 2138-2142, (2006)]
2003-12-15
[Bioorg. Med. Chem. Lett. 13 , 4355-4359, (2003)]
A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy.
2014-06-01
[Exp. Eye Res. 123 , 72-86, (2014)]
2016-01-01
[Sci. Rep. 6 , 29479, (2016)]